craniofacial

By Targets:	Apoptosis (1) Biochemical Assay Reagents (1) COX (2) Endogenous Metabolite (3) ERK (2) FGFR (2) FOXO (1) Fungal (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) mRNA (1) Pyk2 (1) Reference Standards (2)
By Research Areas:	Cancer (5) Infection (1) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (1)
Oligonucleotides:	mRNA (1) Interleukin & Receptors (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0147

Rutaecarpine 5+ Cited Publications Rutecarpine	COX Keap1-Nrf2	Neurological Disease Inflammation/Immunology Cancer
Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC₅₀ value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).

HY-159642

Dabogratinib TYRA-300	FGFR ERK	Metabolic Disease Cancer
Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

HY-18312

PF-4618433 5 Publications Verification	Pyk2	Metabolic Disease
PF-4618433 is a potent and selective PYK2 inhibitor, with an IC₅₀ of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration .

HY-N6786

Ochratoxin B	Endogenous Metabolite	Metabolic Disease
Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-Y0332H

Sodium dihydrogen phosphate dihydrate, for molecular biology Sodium phosphate monobasic dihydrate, for molecular biology	Biochemical Assay Reagents	Others
Sodium dihydrogen phosphate dihydrate (Sodium phosphate monobasic dihydrate), for molecular biology is a phosphate compound and nucleating agent. At a content of 1.2%, Sodium dihydrogen phosphate dihydrate, for molecular biology eliminates the supercooling degree of sodium acetate trihydrate to 0°C while maintaining or slightly enhancing its latent heat storage capacity. Sodium dihydrogen phosphate dihydrate, for molecular biology can serve as a starting material for the synthesis of degradable sodium phosphate glasses, which are applied in craniomaxillofacial bone repair. Sodium dihydrogen phosphate dihydrate, for molecular biology is widely used in research on craniomaxillofacial bone repair and related fields .

HY-B1944

Dipropyl phthalate	Apoptosis FOXO	Others
Dipropyl phthalate is a plasticizer. Dipropyl phthalate induced activation of the FoxO signaling pathway, leading to abnormal proliferation of pharyngeal arch cartilage and promoting its apoptosis in a zebrafish model. Dipropyl phthalate also induced developmental defects in the craniofacial cartilage of zebrafish embryos in a zebrafish model .

HY-159642G

Dabogratinib TYRA-300	FGFR ERK	Metabolic Disease Cancer
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

HY-174643

Human IL11RA mRNA	mRNA	Inflammation/Immunology
Human IL11RA mRNA encodes the human interleukin 11 receptor subunit alpha (IL11RA) protein, a member of the hematopoietic cytokine receptor family. IL11RA is essential for the normal development of craniofacial bones and teeth.

HY-N6786R

Ochratoxin B (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
Ochratoxin B (Standard) is the analytical standard of Ochratoxin B (HY-N6786). This product is intended for research and analytical applications. Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-N6786S

Ochratoxin B-13C20	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Ochratoxin B- ¹³C₂₀ is ¹³C-labeled Ochratoxin B (HY-N6786). Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-N0147R

Rutaecarpine (Standard) Rutecarpine (Standard)	Reference Standards COX Keap1-Nrf2	Inflammation/Immunology Cancer
Rutaecarpine (Standard) is the analytical standard of Rutaecarpine. This product is intended for research and analytical applications. Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC₅₀ value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).

HY-N9367

Soladulcidine	Fungal	Infection Cancer
Soladulcidine, as an anticancer steroidal alkaloid, possesses antifungal and induction of congenital craniofacial malformation activities .

Cat. No.	Product Name	Type

HY-159642G

Dabogratinib TYRA-300	Fluorescent Dyes
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

Dabogratinib

TYRA-300

Fluorescent Dyes

Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

Cat. No.	Product Name	Type

HY-Y0332H

Sodium dihydrogen phosphate dihydrate, for molecular biology Sodium phosphate monobasic dihydrate, for molecular biology	Biochemical Assay Reagents
Sodium dihydrogen phosphate dihydrate (Sodium phosphate monobasic dihydrate), for molecular biology is a phosphate compound and nucleating agent. At a content of 1.2%, Sodium dihydrogen phosphate dihydrate, for molecular biology eliminates the supercooling degree of sodium acetate trihydrate to 0°C while maintaining or slightly enhancing its latent heat storage capacity. Sodium dihydrogen phosphate dihydrate, for molecular biology can serve as a starting material for the synthesis of degradable sodium phosphate glasses, which are applied in craniomaxillofacial bone repair. Sodium dihydrogen phosphate dihydrate, for molecular biology is widely used in research on craniomaxillofacial bone repair and related fields .

Sodium dihydrogen phosphate dihydrate, for molecular biology

Sodium phosphate monobasic dihydrate, for molecular biology

Biochemical Assay Reagents

Sodium dihydrogen phosphate dihydrate (Sodium phosphate monobasic dihydrate), for molecular biology is a phosphate compound and nucleating agent. At a content of 1.2%, Sodium dihydrogen phosphate dihydrate, for molecular biology eliminates the supercooling degree of sodium acetate trihydrate to 0°C while maintaining or slightly enhancing its latent heat storage capacity. Sodium dihydrogen phosphate dihydrate, for molecular biology can serve as a starting material for the synthesis of degradable sodium phosphate glasses, which are applied in craniomaxillofacial bone repair. Sodium dihydrogen phosphate dihydrate, for molecular biology is widely used in research on craniomaxillofacial bone repair and related fields .

HY-159642G

Dabogratinib TYRA-300	Biochemical Assay Reagents
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

Dabogratinib

TYRA-300

Biochemical Assay Reagents

Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0147

Rutaecarpine 5+ Cited Publications Rutecarpine	Alkaloids Structural Classification Classification of Application Fields Evodia rutaecarpa (Juss.) Benth. Rutaceae Plants Disease Research Fields Indole Alkaloids Source Classification Cancer	COX Keap1-Nrf2
Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC₅₀ value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).

HY-N6786

Ochratoxin B	Structural Classification Monophenols Microorganisms Classification of Application Fields Coumarins Phenols Phenylpropanoids Disease Research Fields Source Classification Cancer	Endogenous Metabolite
Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-N6786R

Ochratoxin B (Standard)	Structural Classification Monophenols Microorganisms Coumarins Phenols Phenylpropanoids Source Classification	Endogenous Metabolite Reference Standards
Ochratoxin B (Standard) is the analytical standard of Ochratoxin B (HY-N6786). This product is intended for research and analytical applications. Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-N0147R

Rutaecarpine (Standard) Rutecarpine (Standard)	Alkaloids Structural Classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Plants Indole Alkaloids Source Classification	Reference Standards COX Keap1-Nrf2
Rutaecarpine (Standard) is the analytical standard of Rutaecarpine. This product is intended for research and analytical applications. Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC₅₀ value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).

HY-N9367

Soladulcidine	Infection Structural Classification Classification of Application Fields Solanaceae Plants Disease Research Fields Steroids Solanum dulcamara L. Source Classification	Fungal
Soladulcidine, as an anticancer steroidal alkaloid, possesses antifungal and induction of congenital craniofacial malformation activities .

Cat. No.	Product Name	Chemical Structure

HY-N6786S

Ochratoxin B-13C20
Ochratoxin B- ¹³C₂₀ is ¹³C-labeled Ochratoxin B (HY-N6786). Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

Cat. No.	Product Name		Classification

HY-174643

Human IL11RA mRNA		mRNA Interleukin & Receptors
Human IL11RA mRNA encodes the human interleukin 11 receptor subunit alpha (IL11RA) protein, a member of the hematopoietic cytokine receptor family. IL11RA is essential for the normal development of craniofacial bones and teeth.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159642G

Dabogratinib TYRA-300	FGFR ERK	Metabolic Disease Cancer
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Name
Email *

	Sorry, but the email address you supplied was invalid.

craniofacial

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products